SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aarti Pharmalabs - Quaterly Results

07 Feb 2024 Evaluate
The quarter ended December 2023 witnessed marginal change in the total revenue. The figure for the mentioned quarter is pegged at Rs. 3730.30 millions.The company has announced a 25.04% increase in its profits to Rs . 481.90  millions for the  quarter ended December 2023 compared to Rs. 385.40 millions in the corresponding quarter in the previous year.Operating profit for the quarter ended December 2023 rose to 884.80 millions as compared to 726.00 millions of corresponding quarter ended December 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 3730.30 3593.30 3.81 10873.10 11369.80 -4.37 15112.50 9410.20 60.60
Other Income 2.00 0.40 400.00 50.60 12.80 295.31 12.80 25.10 -49.00
PBIDT 884.80 726.00 21.87 2438.80 2328.10 4.75 3096.20 1822.90 69.85
Interest 41.00 51.20 -19.92 119.50 146.90 -18.65 204.90 113.40 80.69
PBDT 843.80 674.80 25.04 2319.30 2181.20 6.33 2891.30 1709.50 69.13
Depreciation 169.40 145.60 16.35 487.00 415.20 17.29 557.70 372.30 49.80
PBT 674.40 529.20 27.44 1832.30 1766.00 3.75 2333.60 1337.20 74.51
TAX 192.50 143.80 33.87 456.00 448.80 1.60 616.30 270.00 128.26
Deferred Tax 62.50 22.50 177.78 112.50 67.50 66.67 95.00 45.00 111.11
PAT 481.90 385.40 25.04 1376.30 1317.20 4.49 1717.30 1067.20 60.92
Equity 453.10 453.10 0.00 453.10 453.10 0.00 453.10 455.60 -0.55
PBIDTM(%) 23.72 20.20 17.40 22.43 20.48 9.54 20.49 19.37 5.76

Aarti Pharmalabs Share Price

696.60 -2.85 (-0.41%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×